VCYT today
$24.33-$0.30 (-1.22%)close Nov 13, 2026Trend
DailyUptrend (confirmed)
4 hourLeaning Bullish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns down below $41.22
Key levels
Resistance$31.95
Resistance$26.61
Support$22.61
Support$18.61
Latest news & SEC filings
AnalystVeracyte Keeps Overweight Stance From Stephens & Co.
AnalystStephens & Co. keeps Overweight rating on Veracyte, cuts price target to $40
All VCYT news →About Veracyte
Veracyte is a molecular diagnostics company that develops and sells genomic tests for cancer and other diseases. Its main products include the Afirma thyroid test, Decipher Prostate and Bladder tests, and the Prosigna breast cancer assay. The company serves physicians, hospitals, and clinical laboratories, operating in the United States and international markets.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
VERACYTE, INC. (VCYT)
What Is the Price Target for VCYT?
SEPT Low Target
$44.20
SEPT Mid Target
$52.00
SEPT High Target
$59.80
Analyst Consensus
$52.00
Is VCYT a Buy or Sell Right Now?
Thesis
- •Revenue growing 16.0% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for VCYT.
Start Free Trial →Is VCYT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$59.06
66
Moat Score
NARROW
8/9
Piotroski Score
26.6
Altman Z-Score
What Is Smart Money Doing with VCYT?
Insider Signal
SELLING
0 buys / 11 sells (90d)
Congress Signal
BUYING
1 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Wygant Jonathan | officer | Sale | 1,306 | $66K | Oct 28, 2026 |
| EASTHAM KARIN | director | Buy | 10,000 | $270K | Oct 27, 2026 |
| EASTHAM KARIN | director | Sale | 14,850 | $743K | Oct 27, 2026 |
| Holstein Jens | director | Buy | 7,500 | $265K | Oct 27, 2026 |
| Holstein Jens | director | Sale | 7,500 | $375K | Oct 27, 2026 |
| Bhanji Muna | director | Sale | 1,864 | $81K | Oct 19, 2026 |
| Holstein Jens | director | Buy | 7,500 | $265K | Sep 24, 2026 |
| Holstein Jens | director | Sale | 7,500 | $353K | Sep 24, 2026 |
| Leite John | officer | Sale | 4,015 | $161K | Sep 21, 2026 |
| McGuire Annie | officer | Sale | 2,154 | $92K | Sep 4, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →VCYT Growth Story
Revenue YoY
16.0%
3yr Revenue CAGR
20.4%
EPS Growth YoY
164.52%
FCF Growth YoY
98.5%
Revenue Trend
STRONG
Dark Pool Trades for VCYT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for VCYT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:12:23 | $24.16 | 1,000 | $$24K | SELL |
| 18:02:03 | $24.19 | 1,096 | $$27K | SELL |
| 18:01:24 | $24.25 | 2,100 | $$51K | SELL |
| 18:01:24 | $24.25 | 2,700 | $$65K | SELL |
| 18:01:24 | $24.25 | 2,572 | $$62K | SELL |
5 dark pool trades shown · $$229K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for VERACYTE, INC. (VCYT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →VCYT — frequently asked questions
What is VCYT stock price today?
VERACYTE, INC. (VCYT) is at $24.33, down 1.22% (-$0.30) at the Nov 13, 2026 close.
Why is VCYT stock moving today?
Latest VCYT news — Nov 12, 2026: Veracyte Keeps Overweight Stance From Stephens & Co. · Nov 11, 2026: Stephens & Co. keeps Overweight rating on Veracyte, cuts price target to $40
What is the VCYT price target?
The average analyst price target for VCYT is $52.00, ranging from $44 to $69, based on 10 analysts. Latest: UBS maintains on Sep 9, 2026.
What do analysts rate VCYT?
Analyst ratings for VCYT: 2 Buy, 17 Hold, 0 Sell — consensus Hold.
Did VCYT beat earnings?
VCYT last reported on Jul 30, 2026: EPS $0.54 vs $0.41 expected — a beat of 31.6%.
What is VCYT's P/E ratio?
VCYT trades at a P/E of 35.7 vs a Healthcare average of 17.5.
Does VCYT pay a dividend?
VCYT does not currently pay a dividend.
What are VCYT support and resistance levels?
Support: $22.61, $18.61. Resistance: $26.61, $31.95, $38.24.
What are insiders doing with VCYT?
Insider activity: SELLING, 0 buys and 11 sells in the last 90 days.
What is the latest news on VCYT?
Nov 12, 2026: Veracyte Keeps Overweight Stance From Stephens & Co. · Nov 11, 2026: Stephens & Co. keeps Overweight rating on Veracyte, cuts price target to $40